DIA EUROPE 2021

Neoadjuvant and adjuvant treatments have shown promising results for a while, but broad use still faces many challenges. As value demonstration and appreciation remains difficult, uncertainties around neoadjuvant and adjuvant treatments persist. The goal of this spotlight session is to re-visit these uncertainties and to explore potential pathways to managing them from the perspective of patients, HTA bodies, payers, and industry. - What type and degree of information do patients need to understand their options in neoadjuvant and adjuvant settings and balance the benefits and risks associated with these options? - How can HTA bodies and payers mitigate uncertainty in their funding decisions and help broaden patients’ access to innovative early treatments while ensuring the sustainability of healthcare systems? - How can industry help to demonstrate the value of new oncology treatments to patients and healthcare systems as well as develop the frameworks in which new treatments are assessed by patients and payers?